The LinkedIn B2B Institute, in partnership with WARC, has released a new report, titled ‘Making a Promise to the Customer‘, exploring the strategic framework of the ‘Promise to the Customer’ (PTTC). Developed with insights from renowned strategist Roger Martin, this model seeks to align diverse business functions—marketing, sales, product development, and customer experience—around a coherent, credible promise to the customer.Â
By studying over 2,000 advertising campaigns, the report underscores the superior performance of PTTC campaigns in key metrics such as brand health, market share, and long-term sales growth.Â
Below, we delve into the essential findings and implications of this report:
Impact on Brand Health:
Market Share and Penetration:
Creative Effectiveness Ladder:
The “Promise to the Customer” (PTTC) model elucidated by the LinkedIn B2B Institute and WARC underscores a transformative approach for aligning business functions around a cohesive customer promise.Â
This strategic alignment not only boosts brand health by 56% but also demonstrates significant gains in market share and long-term sales growth.Â
For pharmaceutical marketers, the PTTC model opens new potential avenues for customer engagement and trust-building. One may put ViiV’s strapline of ‘HERE UNTIL HIV ISN’T’ into this category of PTTC. It is clear, consistent and memorable.Â
However, PTTC campaigns do need to be considered carefully within pharma media:
To read the full report, click here.